SUPPLEMENT

Q2 2024 — Financial disclosures

Q2 2024PDF · 10 pages1.1 MB
Merck & Co., Inc.
Financial Highlights Package
Second Quarter 2024
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 2Q24 and June YTD 24.......3
Table 2b: GAAP to Non-GAAP Reconciliation 2Q23 and June YTD 23.......4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / Ex- U.S. 2Q24........................................................6
Table 3b: Sales – U.S. / Ex- U.S. June YTD 24............................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	15,775	$ 	16,112	$ 	31,887	$ 	14,487	$ 	15,035	$ 	29,522	$ 	15,962	$ 	14,630	$ 	60,115	$ 	7% 	8%
Costs, Expenses and Other
Cost of sales 	3,540 	3,745 	7,285 	3,926 	4,024 	7,951 	4,264 	3,911 	16,126 	-7% 	-8%
Selling, general and administrative 	2,483 	2,739 	5,221 	2,479 	2,702 	5,182 	2,519 	2,804 	10,504 	1% 	1%
Research and development 	3,992 	3,500 	7,492 	4,276 	13,321 	17,597 	3,307 	9,628 	30,531 	-74% 	-57%
Restructuring costs 	123 	80 	202 	67 	151 	218 	126 	255 	599 	-47% 	-7%
Other (income) expense, net 	(33) 	42 	12 	89 	172 	259 	126 	78 	466 	-76% 	-95%
Income (Loss) Before Taxes 	5,670 	6,006 	11,675 	3,650 	(5,335) 	(1,685) 	5,620 	(2,046) 	1,889 	* 	*
Income Tax Provision (Benefit) 	903 	545 	1,447 	825 	637 	1,462 	870 	(821) 	1,512
Net Income (Loss) 	4,767 	5,461 	10,228 	2,825 	(5,972) 	(3,147) 	4,750 	(1,225) 	377 	* 	*
Less: Net Income Attributable to Noncontrolling Interests 	5 	6 	11 	4 	3 	7 	5 	1 	12
Net Income (Loss) Attributable to Merck & Co., Inc. 	4,762	$ 	5,455	$ 	10,217	$ 	2,821	$ 	(5,975)	$ 	(3,154)	$ 	4,745	$ 	(1,226)	$ 	365	$ 	* 	*
Earnings (Loss) per Common Share Assuming Dilution (1) 	1.87	$ 	2.14	$ 	4.02	$ 	1.11	$ 	(2.35)	$ 	(1.24)	$ 	1.86	$ 	(0.48)	$ 	0.14	$ 	* 	*
Average Shares Outstanding Assuming Dilution (1) 	2,544 	2,544 	2,544 	2,551 	2,539 	2,539 	2,546 	2,533 	2,547
Tax Rate 	15.9% 	9.1% 	12.4% 	22.6% 	-11.9% 	-86.8% 	15.5% 	40.1% 	80.0%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
June
YTD
% Change
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
2Q
(1) Because the company recorded a net loss in the second quarter and first six months of 2023, as well as the fourth quarter of 2023, no potential dilutive common shares were used in the computation
of loss per common share assuming dilution as the effect would have been anti-dilutive.
2024
2Q 	June YTD	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2023
June YTD
1

-- 2 of 10 --

Sales 	16,112	$ 	15,035	$ 	7% 	31,887	$ 	29,522	$ 	8%
Costs, Expenses and Other
Cost of sales 	3,745 	4,024 	-7% 	7,285 	7,951 	-8%
Selling, general and administrative 	2,739 	2,702 	1% 	5,221 	5,182 	1%
Research and development 	3,500 	13,321 	-74% 	7,492 	17,597 	-57%
Restructuring costs 	80 	151 	-47% 	202 	218 	-7%
Other (income) expense, net 	42 	172 	-76% 	12 	259 	-95%
Income (Loss) Before Taxes 	6,006 	(5,335) 	* 	11,675 	(1,685) 	*
Income Tax Provision 	545 	637 	1,447 	1,462
Net Income (Loss) 	5,461 	(5,972) 	* 	10,228 	(3,147) 	*
Less: Net Income Attributable to Noncontrolling Interests 	6 	3 	11 	7
Net Income (Loss) Attributable to Merck & Co., Inc. 	5,455	$ 	(5,975)	$ 	* 	10,217	$ 	(3,154)	$ 	*
Earnings (Loss) per Common Share Assuming Dilution (1) 	2.14	$ 	(2.35)	$ 	* 	4.02	$ 	(1.24)	$ 	*
Average Shares Outstanding Assuming Dilution (1) 	2,544 	2,539 	2,544 	2,539
Tax Rate 	9.1% 	-11.9% 	12.4% 	-86.8%
* 100% or greater
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
(1) Because the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used in the computation of loss per common
share assuming dilution as the effect would have been anti-dilutive.
GAAP
% Change
2Q24 	2Q23
GAAP
% Change	June YTD
2024
June YTD
2023
2

-- 3 of 10 --

Second Quarter
Cost of sales 	3,745	$ 	606 	66 	672 	3,073	$
Selling, general and administrative 	2,739 	24 	31 	55 	2,684
Research and development 	3,500 	20 	20 	3,480
Restructuring costs 	80 	80 	80 	–
Other (income) expense, net 	42 	(17) 	(49) 	(66) 	108
Income Before Taxes 	6,006 	(633) 	(177) 	49 	(761) 	6,767
Income Tax Provision (Benefit) 	545 	(129) (3) 	(30) (3) 	11 (3) 	(259) (4) 	(407) 	952
Net Income 	5,461 	(504) 	(147) 	38 	259 	(354) 	5,815
Net Income Attributable to Merck & Co., Inc. 	5,455 	(504) 	(147) 	38 	259 	(354) 	5,809
Earnings per Common Share Assuming Dilution 	2.14	$ 	(0.20) 	(0.06) 	0.02 	0.10 	(0.14) 	2.28	$
Tax Rate 	9.1% 	14.1%
June YTD
Cost of sales 	7,285	$ 	1,069 	182 	1,251 	6,034	$
Selling, general and administrative 	5,221 	45 	36 	81 	5,140
Research and development 	7,492 	36 	2 	38 	7,454
Restructuring costs 	202 	202 	202 	–
Other (income) expense, net 	12 	(21) 	(165) 	(186) 	198
Income Before Taxes 	11,675 	(1,129) 	(422) 	165 	(1,386) 	13,061
Income Tax Provision (Benefit) 	1,447 	(221) (3) 	(72) (3) 	36 (3) 	(259) (4) 	(516) 	1,963
Net Income 	10,228 	(908) 	(350) 	129 	259 	(870) 	11,098
Net Income Attributable to Merck & Co., Inc. 	10,217 	(908) 	(350) 	129 	259 	(870) 	11,087
Earnings per Common Share Assuming Dilution 	4.02	$ 	(0.35) 	(0.14) 	0.05 	0.10 	(0.34) 	4.36	$
Tax Rate 	12.4% 	15.0%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
THREE AND SIX MONTHS ENDED JUNE 30, 2024 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
(4) Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.
Adjustment Subtotal 	Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing
non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting
purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The
non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to
acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the
prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
3

-- 4 of 10 --

Second Quarter
Cost of sales 	4,024	$ 	467 	32 	499 	3,525	$
Selling, general and administrative 	2,702 	25 	52 	77 	2,625
Research and development 	13,321 	9 	1 	10 	13,311
Restructuring costs 	151 	151 	151 	-
Other (income) expense, net 	172 	(3) 	194 	191 	(19)
Loss Before Taxes 	(5,335) 	(498) 	(236) 	(194) 	(928) 	(4,407)
Income Tax Provision (Benefit) 	637 	(91) (4) 	(38) (4) 	(44) (4) 	(173) 	810
Net Loss 	(5,972) 	(407) 	(198) 	(150) 	(755) 	(5,217)
Net Loss Attributable to Merck & Co., Inc. 	(5,975) 	(407) 	(198) 	(150) 	(755) 	(5,220)
Loss per Common Share Assuming Dilution (5) 	(2.35)	$ 	(0.16) 	(0.07) 	(0.06) 	(0.29) 	(2.06)	$
Tax Rate 	-11.9% 	-18.4%
June YTD
Cost of sales 	7,951	$ 	1,012 	61 	1,073 	6,878	$
Selling, general and administrative 	5,182 	45 	53 	98 	5,084
Research and development 	17,597 	19 	1 	20 	17,577
Restructuring costs 	218 	218 	218 	-
Other (income) expense, net 	259 	12 	(235) 	573 (3) 	350 	(91)
(Loss) Income Before Taxes 	(1,685) 	(1,088) 	(333) 	235 	(573) 	(1,759) 	74
Income Tax Provision (Benefit) 	1,462 	(196) (4) 	(56) (4) 	51 (4) 	(60) (4) 	(261) 	1,723
Net Loss 	(3,147) 	(892) 	(277) 	184 	(513) 	(1,498) 	(1,649)
Net Loss Attributable to Merck & Co., Inc. 	(3,154) 	(892) 	(277) 	184 	(513) 	(1,498) 	(1,656)
Loss per Common Share Assuming Dilution (5) 	(1.24)	$ 	(0.35) 	(0.11) 	0.07 	(0.20) 	(0.59) 	(0.65)	$
Tax Rate 	-86.8% 	2,328.4%
Only the line items that are affected by non-GAAP adjustments are shown.
(5) Because the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have
been anti-dilutive.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and
forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax
income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to
acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the six-month period
primarily reflect a $37 million loss on the sale of a business and an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture, partially
offset by royalty income.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
THREE AND SIX MONTHS ENDED JUNE 30, 2023 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
4

-- 5 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2024 	2023 	2Q 	June YTD
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$15,775 	$16,112 	$31,887 	$14,487 	$15,035 	$29,522 	$15,962 	$14,630 	$60,115 	7 	11 	8 	11
PHARMACEUTICAL 	14,006 	14,408 	28,415 	12,721 	13,457 	26,179 	14,263 	13,141 	53,583 	7 	11 	9 	12
Oncology
Keytruda 	6,947 	7,270 	14,217 	5,795 	6,271 	12,065 	6,338 	6,608 	25,011 	16 	21 	18 	22
Alliance Revenue – Lynparza (2) 	292 	317 	609 	275 	310 	585 	299 	315 	1,199 	2 	4 	4 	6
Alliance Revenue – Lenvima (2) 	255 	249 	504 	232 	242 	474 	260 	226 	960 	3 	4 	6 	7
Welireg 	85 	126 	211 	42 	50 	92 	54 	72 	218 	150 	150 	128 	128
Alliance Revenue – Reblozyl (3) 	71 	90 	161 	43 	47 	90 	52 	70 	212 	92 	92 	80 	80
Vaccines (4)
Gardasil/Gardasil 9 	2,249 	2,478 	4,727 	1,972 	2,458 	4,430 	2,585 	1,871 	8,886 	1 	4 	7 	10
ProQuad/M-M-R II/Varivax 	570 	617 	1,187 	528 	582 	1,109 	713 	545 	2,368 	6 	7 	7 	7
Vaxneuvance 	219 	189 	408 	106 	168 	274 	214 	176 	665 	13 	16 	49 	51
RotaTeq 	216 	163 	379 	297 	131 	428 	156 	185 	769 	25 	26 	-11 	-10
Pneumovax 23 	61 	59 	120 	96 	92 	188 	140 	85 	412 	-36 	-32 	-36 	-32
Hospital Acute Care
Bridion 	440 	455 	895 	487 	502 	989 	424 	429 	1,842 	-9 	-8 	-9 	-8
Prevymis 	174 	188 	362 	129 	143 	273 	157 	175 	605 	31 	35 	33 	37
Dificid 	73 	92 	165 	65 	76 	141 	74 	87 	302 	20 	20 	16 	16
Zerbaxa 	56 	62 	118 	50 	54 	104 	53 	61 	218 	14 	18 	13 	16
Noxafil 	56 	45 	101 	60 	55 	116 	51 	46 	213 	-20 	-9 	-13 	-2
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	98 	106 	203 	99 	68 	167 	92 	108 	367 	56 	56 	22 	22
Adempas (6) 	70 	72 	142 	59 	65 	125 	65 	66 	255 	11 	15 	14 	17
Winrevair 	70 	70 	- 	- 	- 	-
Virology
Lagevrio 	350 	110 	460 	392 	203 	595 	640 	193 	1,428 	-46 	-42 	-23 	-18
Isentress/Isentress HD 	111 	89 	200 	123 	136 	259 	119 	105 	483 	-35 	-31 	-23 	-19
Delstrigo 	56 	60 	116 	44 	50 	94 	54 	54 	201 	19 	23 	23 	26
Pifeltro 	42 	39 	81 	34 	38 	72 	37 	33 	142 	3 	4 	13 	13
Neuroscience
Belsomra 	46 	53 	99 	56 	63 	119 	58 	54 	231 	-16 	-8 	-17 	-10
Immunology
Simponi 	184 	172 	356 	180 	180 	359 	179 	171 	710 	-4 	-2 	-1 	-1
Remicade 	39 	35 	74 	51 	48 	99 	45 	43 	187 	-27 	-20 	-25 	-21
Diabetes (7)
Januvia 	419 	405 	824 	551 	511 	1,062 	581 	547 	2,189 	-21 	-16 	-22 	-19
Janumet 	251 	224 	475 	329 	354 	683 	255 	240 	1,177 	-37 	-32 	-30 	-26
Other Pharmaceutical (8) 	576 	573 	1,151 	626 	560 	1,187 	568 	576 	2,333 	2 	6 	-3 	-1
ANIMAL HEALTH 	1,511 	1,482 	2,993 	1,491 	1,456 	2,947 	1,400 	1,278 	5,625 	2 	6 	2 	5
Livestock 	850 	837 	1,686 	849 	807 	1,656 	874 	808 	3,337 	4 	11 	2 	7
Companion Animal 	661 	645 	1,307 	642 	649 	1,291 	526 	470 	2,288 	-1 	1 	1 	3
Other Revenues (9) 	258 	222 	479 	275 	122 	396 	299 	211 	907 	82 	53 	21 	24
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Total Diabetes sales were $745 million and $715 million in the first and second quarter of 2024, respectively, and $950 million and $951 million in the first and second quarter of 2023,
respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other
Revenues related to the receipt of upfront and milestone payments for out-licensed products were $61 million and $15 million in the first and second quarter of 2024, respectively, and $51
million and $3 million in the first and second quarter of 2023, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $3,424 million and $3,656 million in the first and second quarter of 2024, respectively, and $3,133 million and $3,557 million in the first and second quarter of
2023, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
5

-- 6 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SECOND QUARTER 2024
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
2Q 2024 	2Q 2023 % Change 	2Q 2024 	2Q 2023 % Change 	2Q 2024 	2Q 2023 % Change
TOTAL SALES (1) 	$16,112 	$15,035 	7 	$7,876 	$7,018 	12 	$8,236 	$8,018 	3
PHARMACEUTICAL 	14,408 	13,457 	7 	7,399 	6,570 	13 	7,009 	6,887 	2
Oncology
Keytruda 	7,270 	6,271 	16 	4,412 	3,863 	14 	2,858 	2,408 	19
Alliance Revenue – Lynparza (2) 	317 	310 	2 	153 	144 	6 	165 	166 	-1
Alliance Revenue – Lenvima (2) 	249 	242 	3 	177 	163 	8 	73 	79 	-7
Welireg 	126 	50 	150 	116 	49 	138 	10 	2 	*
Alliance Revenue – Reblozyl (3) 	90 	47 	92 	75 	36 	110 	15 	11 	36
Vaccines (4)
Gardasil/Gardasil 9 	2,478 	2,458 	1 	536 	464 	16 	1,941 	1,994 	-3
ProQuad/M-M-R II/Varivax 	617 	582 	6 	490 	447 	10 	127 	135 	-6
Vaxneuvance 	189 	168 	13 	99 	147 	-33 	90 	20 	*
RotaTeq 	163 	131 	25 	107 	93 	15 	56 	37 	50
Pneumovax 23 	59 	92 	-36 	11 	23 	-54 	48 	69 	-30
Hospital Acute Care
Bridion 	455 	502 	-9 	351 	299 	17 	104 	203 	-49
Prevymis 	188 	143 	31 	90 	61 	47 	98 	82 	19
Dificid 	92 	76 	20 	79 	68 	16 	12 	8 	56
Zerbaxa 	62 	54 	14 	33 	30 	12 	28 	24 	17
Noxafil 	45 	55 	-20 	11 	N/M 	44 	45 	-1
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	106 	68 	56 	98 	70 	41 	8 	-2 	*
Adempas (6) 	72 	65 	11 	72 	65 	11
Winrevair 	70 	- 	70 	-
Virology
Lagevrio 	110 	203 	-46 	15 	2 	* 	95 	201 	-53
Isentress/Isentress HD 	89 	136 	-35 	43 	56 	-24 	46 	80 	-42
Delstrigo 	60 	50 	19 	14 	13 	13 	45 	37 	21
Pifeltro 	39 	38 	3 	27 	27 	-1 	12 	11 	15
Neuroscience
Belsomra 	53 	63 	-16 	19 	21 	-12 	34 	42 	-18
Immunology
Simponi 	172 	180 	-4 	172 	180 	-4
Remicade 	35 	48 	-27 	35 	48 	-27
Diabetes (7)
Januvia 	405 	511 	-21 	177 	243 	-27 	227 	267 	-15
Janumet 	224 	354 	-37 	17 	82 	-80 	208 	272 	-24
Other Pharmaceutical (8) 	573 	560 	2 	190 	158 	20 	386 	403 	-4
ANIMAL HEALTH 	1,482 	1,456 	2 	455 	475 	-4 	1,027 	982 	5
Livestock 	837 	807 	4 	168 	165 	2 	669 	643 	4
Companion Animal 	645 	649 	-1 	287 	310 	-7 	358 	339 	6
Other Revenues (9) 	222 	122 	82 	22 	-27 	-181 	200 	149 	34
*200% or greater
N/M - Not Meaningful
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $715 million in the second quarter of 2024, and $951 million in the second quarter of 2023.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$15 million in the second quarter of 2024 and $3 million in the second quarter of 2023.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $3,656 million in the second quarter of 2024 and $3,557 million in the second quarter of 2023.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs.
6

-- 7 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
June YTD
2024
June YTD
2023 	% Change
June YTD
2024
June YTD
2023 	% Change
June YTD
2024
June YTD
2023 	% Change
TOTAL SALES (1) 	$31,887 	$29,522 	8 	$15,354 	$13,676 	12 	$16,533 	$15,846 	4
PHARMACEUTICAL 	28,415 	26,179 	9 	14,336 	12,688 	13 	14,079 	13,491 	4
Oncology
Keytruda 	14,217 	12,065 	18 	8,531 	7,348 	16 	5,686 	4,718 	21
Alliance Revenue – Lynparza (2) 	609 	585 	4 	288 	286 	1 	321 	299 	7
Alliance Revenue – Lenvima (2) 	504 	474 	6 	349 	316 	10 	155 	158 	-2
Welireg 	211 	92 	128 	194 	90 	116 	17 	3 	*
Alliance Revenue – Reblozyl (3) 	161 	90 	80 	133 	66 	102 	28 	24 	17
Vaccines (4)
Gardasil/Gardasil 9 	4,727 	4,430 	7 	1,024 	880 	16 	3,702 	3,550 	4
ProQuad/M-M-R II/Varivax 	1,187 	1,109 	7 	928 	868 	7 	259 	242 	7
Vaxneuvance 	408 	274 	49 	260 	241 	8 	148 	33 	*
RotaTeq 	379 	428 	-11 	257 	273 	-6 	123 	155 	-21
Pneumovax 23 	120 	188 	-36 	17 	63 	-73 	103 	125 	-17
Hospital Acute Care
Bridion 	895 	989 	-9 	680 	576 	18 	215 	413 	-48
Prevymis 	362 	273 	33 	165 	116 	42 	197 	157 	26
Dificid 	165 	141 	16 	147 	130 	13 	17 	11 	54
Zerbaxa 	118 	104 	13 	67 	57 	17 	51 	47 	9
Noxafil 	101 	116 	-13 	8 	25 	-67 	92 	91 	2
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	203 	167 	22 	188 	153 	23 	16 	14 	11
Adempas (6) 	142 	125 	14 	142 	125 	14
Winrevair 	70 	- 	70 	-
Virology
Lagevrio 	460 	595 	-23 	60 	- 	400 	595 	-33
Isentress/Isentress HD 	200 	259 	-23 	93 	108 	-14 	107 	151 	-29
Delstrigo 	116 	94 	23 	26 	24 	11 	89 	70 	27
Pifeltro 	81 	72 	13 	56 	51 	9 	25 	21 	20
Neuroscience
Belsomra 	99 	119 	-17 	33 	37 	-10 	66 	82 	-19
Immunology
Simponi 	356 	359 	-1 	356 	359 	-1
Remicade 	74 	99 	-25 	74 	99 	-25
Diabetes (7)
Januvia 	824 	1,062 	-22 	361 	514 	-30 	463 	548 	-15
Janumet 	475 	683 	-30 	55 	138 	-60 	420 	544 	-23
Other Pharmaceutical (8) 	1,151 	1,187 	-3 	346 	328 	5 	807 	857 	-6
ANIMAL HEALTH 	2,993 	2,947 	2 	929 	956 	-3 	2,064 	1,991 	4
Livestock 	1,686 	1,656 	2 	334 	338 	-1 	1,352 	1,318 	3
Companion Animal 	1,307 	1,291 	1 	595 	618 	-4 	712 	673 	6
Other Revenues (9) 	479 	396 	21 	89 	32 	178 	390 	364 	7
*200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,461 million and $1,901 million on a global basis for June YTD 2024 and 2023, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $76
million and $54 million on a global basis for June YTD 2024 and 2023, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $7,080 million and $6,690 million on a global basis for June YTD 2024 and 2023, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
7

-- 8 of 10 --

#
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2024 	2023 	% Change
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	2Q 	June YTD
TOTAL PHARMACEUTICAL 	$14,006 	$14,408 	$28,415 	$12,721 	$13,457 	$26,179 	$14,263 	$13,141 	$53,583 	7 	9
United States 	6,936 	7,399 	14,336 	6,117 	6,570 	12,688 	7,153 	6,698 	26,539 	13 	13
% Pharmaceutical Sales 	49.5% 	51.4% 	50.5% 	48.1% 	48.8% 	48.5% 	50.1% 	51.0% 	49.5%
Europe (1) 	2,555 	2,572 	5,128 	2,326 	2,401 	4,727 	2,497 	2,491 	9,715 	7 	8
% Pharmaceutical Sales 	18.2% 	17.9% 	18.0% 	18.3% 	17.8% 	18.1% 	17.5% 	19.0% 	18.1%
China 	1,744 	1,790 	3,534 	1,694 	1,887 	3,581 	1,674 	1,456 	6,710 	-5 	-1
% Pharmaceutical Sales 	12.5% 	12.4% 	12.4% 	13.3% 	14.0% 	13.7% 	11.7% 	11.1% 	12.5%
Japan 	802 	664 	1,466 	737 	652 	1,390 	1,062 	629 	3,081 	2 	6
% Pharmaceutical Sales 	5.7% 	4.6% 	5.2% 	5.8% 	4.8% 	5.3% 	7.4% 	4.8% 	5.7%
Latin America 	601 	661 	1,262 	470 	566 	1,036 	696 	596 	2,328 	17 	22
% Pharmaceutical Sales 	4.3% 	4.6% 	4.4% 	3.7% 	4.2% 	4.0% 	4.9% 	4.5% 	4.3%
Asia Pacific (other than China and Japan) 	580 	595 	1,175 	703 	705 	1,409 	636 	616 	2,661 	-16 	-17
% Pharmaceutical Sales 	4.1% 	4.1% 	4.1% 	5.5% 	5.2% 	5.4% 	4.5% 	4.7% 	5.0%
Eastern Europe/Middle East/Africa 	395 	353 	747 	381 	370 	751 	301 	299 	1,351 	-5 	-1
% Pharmaceutical Sales 	2.8% 	2.4% 	2.6% 	3.0% 	2.7% 	2.9% 	2.1% 	2.3% 	2.5%
Canada 	138 	143 	281 	141 	127 	268 	133 	138 	540 	12 	5
% Pharmaceutical Sales 	1.0% 	1.0% 	1.0% 	1.1% 	0.9% 	1.0% 	0.9% 	1.1% 	1.0%
Other 	255 	231 	486 	152 	179 	329 	111 	218 	658 	29 	48
% Pharmaceutical Sales 	1.9% 	1.6% 	1.8% 	1.2% 	1.6% 	1.1% 	0.9% 	1.5% 	1.4%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
2Q24 	2Q23
June YTD
2024
June YTD
2023
Interest income 	(69)	$ 	(109)	$ 	(141)	$ 	(221)	$
Interest expense 	310 	277 	613 	519
Exchange losses 	60 	62 	144 	122
(Income) loss from investments in equity securities, net (1) 	(56) 	175 	(200) 	(274)
Net periodic defined benefit plan (credit) cost other than service cost 	(159) 	(111) 	(319) 	(226)
Other, net 	(44) 	(122) 	(85) 	339
Total 	42	$ 	172	$ 	12	$ 	259	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment
funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from
ownership interests in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --